دورية أكاديمية
Bimatoprost SR for Glaucoma Therapy Implanted at the Slit-Lamp in a Real-World Setting.
| العنوان: | Bimatoprost SR for Glaucoma Therapy Implanted at the Slit-Lamp in a Real-World Setting. |
|---|---|
| المؤلفون: | Ali AA; Anne Burnett Marion School of Medicine, Texas Christian University, Fort Worth, TX, USA., Avilés Elescano D; Universidad San Martin de Porres (USMP), Lima, Peru., Grover DS; Glaucoma Associates of Texas, Dallas, TX, USA. |
| المصدر: | Clinical ophthalmology (Auckland, N.Z.) [Clin Ophthalmol] 2024 May 15; Vol. 18, pp. 1371-1377. Date of Electronic Publication: 2024 May 15 (Print Publication: 2024). |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Dove Medical Press Country of Publication: New Zealand NLM ID: 101321512 Publication Model: eCollection Cited Medium: Print ISSN: 1177-5467 (Print) Linking ISSN: 11775467 NLM ISO Abbreviation: Clin Ophthalmol Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: Auckland : Dove Medical Press, c2007- |
| مستخلص: | Purpose: To characterize clinical outcomes following a single administration of bimatoprost SR in eyes with glaucoma in a real-world setting implanted at the slit-lamp. Setting: Tertiary care Glaucoma practice, Glaucoma Associates of Texas, Dallas, Texas. Design: Retrospective interventional case series. Methods: Data were analyzed from consecutive patients receiving a single bimatoprost SR implant from the time of its approval to the time of data collection. All eyes were implanted at the slit-lamp. Eyes with less than 1 month of follow-up were excluded. The primary outcome was median time to next intraocular pressure (IOP)-lowering intervention. Mean IOP and medication use, and changes from baseline, were also assessed through 12 months of follow-up. Results: Overall 129 eyes of 81 patients were analyzed. Following bimatoprost SR administration (replacing a topical prostaglandin analogue [PGA] in most eyes), the median survival time without any further IOP-lowering interventions was between 6-9 months. Mean IOP remained unchanged from baseline at month 1 (consistent with switch from topical to intracameral PGA therapy) and began to rise at month 3. At month 12, 40.5% of eyes (52 eyes) remained intervention-free, mean medication reduction was 0.5 medications per eye, and 27.8% of eyes (36 eyes) were medication-free. Adverse events were uncommon and most were transient and resolved with or without intervention. Conclusion: This real-world analysis of bimatoprost SR use for glaucoma therapy complements Phase 3 study findings and demonstrates that the implant can safely provide medication reduction through 6 months in most eyes and through 12 months in almost 40% of eyes. Competing Interests: DSG is a consultant for Allergan and reports grants/personal fees for Medical Advisory Board from Belkin Vision, CATS tonometer, Reichert, Sanoculis, Versant Health and iStar Medical; grants/personal fees from New World Medical and Regeneron; personal fees and minority equity ownership from Nova Eye Medical and Olleyes, outside the submitted work. The authors report no other conflicts of interest in this work. (© 2024 Ali et al.) |
| References: | Ophthalmology. 2005 Mar;112(3):366-75. (PMID: 15745761) J Ocul Pharmacol Ther. 2011 Jun;27(3):281-5. (PMID: 21557633) Am J Ophthalmol. 1995 Dec;120(6):718-31. (PMID: 8540545) Drugs. 2021 Nov;81(17):2017-2033. (PMID: 34724172) Cornea. 2010 Jun;29(6):618-21. (PMID: 20386433) Eur J Ophthalmol. 2011 Jul-Aug;21(4):410-4. (PMID: 21140373) J Glaucoma. 2008 Aug;17(5):350-5. (PMID: 18703943) J Fr Ophtalmol. 2024 Feb;47(2):103996. (PMID: 37926661) Arch Ophthalmol. 2002 Jun;120(6):701-13; discussion 829-30. (PMID: 12049574) J Glaucoma. 2023 Sep 1;32(9):738-743. (PMID: 37523637) Arch Ophthalmol. 2002 Oct;120(10):1268-79. (PMID: 12365904) Eur J Ophthalmol. 2013 May-Jun;23(3):296-302. (PMID: 23335308) Ophthalmology. 2020 Dec;127(12):1627-1641. (PMID: 32544560) Ophthalmology. 2001 Nov;108(11):1943-53. (PMID: 11713061) Am J Ophthalmol. 2012 Jan;153(1):1-9.e2. (PMID: 21872203) Optom Vis Sci. 2011 Jan;88(1):36-8. (PMID: 21131876) Ophthalmology. 2005 Jun;112(6):953-61. (PMID: 15885795) Clin Exp Ophthalmol. 2012 Sep-Oct;40(7):675-81. (PMID: 22394358) Cornea. 2012 Sep;31(9):994-9. (PMID: 22710490) Am J Ophthalmol. 1993 Aug 15;116(2):176-81. (PMID: 8352302) Am J Ophthalmol. 1987 Feb 15;103(2):188-93. (PMID: 3812621) Ophthalmology. 2011 Dec;118(12):2398-402. (PMID: 21856009) Drugs. 2020 Feb;80(2):167-179. (PMID: 31884564) |
| فهرسة مساهمة: | Keywords: bimatoprost SR; durysta; glaucoma; sustained release |
| تواريخ الأحداث: | Date Created: 20240520 Latest Revision: 20240521 |
| رمز التحديث: | 20240521 |
| مُعرف محوري في PubMed: | PMC11102741 |
| DOI: | 10.2147/OPTH.S450220 |
| PMID: | 38765460 |
| قاعدة البيانات: | MEDLINE |
PDF full text from Publisher 
Full Text Finder | تدمد: | 1177-5467 |
|---|---|
| DOI: | 10.2147/OPTH.S450220 |